Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model

BACKGROUND: The prevalence of patients with gastrointestinal stromal tumourgst (GIST) who fail currently available treatments imatinib and sunitinib (third-line treatment-eligible GIST) is unknown, but is expected to be below an ultra-orphan disease threshold of 2/100,000 population used in England...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Starczewska Amelio, Justyna M, Cid Ruzafa, Javier, Desai, Kamal, Tzivelekis, Spiros, Muston, Dominic, Khalid, Javaria Mona, Ashman, Philip, Maguire, Andrew
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2014
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4039646/
https://ncbi.nlm.nih.gov/pubmed/24884940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-364
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires